The humanized monoclonal antibody against RANKL (Denosumab) offers improvement over certain bisphosphonates, reduces the risk of bone fracture in breast cancer patients by 50% and delays skeletal-related events [53]. This evidence concerns the gene TNFSF11 and breast carcinoma.